News
Study shows CHLOE AI’s role in advancing reproductive health research
Researchers can use Fairtility’s AI tool to further their understanding of embryo and oocyte development

Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, has announced the highlights of a new study published in Nature’s Scientific Reports.
The study, focused on blastocyst morphometric parameters’ impact on implantation potential, highlights how Fairtility’s transparent AI decision support technology, CHLOE, can support academic research in the field of assisted reproductive technologies.
The study, entitled An artificial intelligence algorithm for automated blastocyst morphometric parameters demonstrates a positive association with implantation potential, was led by Professor Iris Har Vardi, director of Fertility and IVF Lab at Soroka University Medical Center and senior lecturer at Ben Gurion University in the Faculty of Health Sciences. Har Vardi also serves as a scientific advisor to Fairtility.

Automatic measurements of blastocyst morphometrics. (a) A day-5 blastocyst with trophectoderm (TE) and inner cell mass (ICM) cells. (b) The same embryo with markings. Blue represents the hand drawn segmentation around the outer part of the TE cells, excluding the area occupied by the zona pellucida. Green represents the ellipse that best fits around the segmented ICM pixels in the least-squares sense. Red represents the diameter of the embryo.
The study included 608 transferred blastocysts that were selected using morphokinetics and Gardner criteria. Retrospectively, researchers deployed CHLOE to automatically assess four morphometric parameters: blastocyst size, inner cell mass (ICM) size, ICM-to-blastocyst size ratio and ICM shape.
Researchers found that blastocyst size had a significant positive association with implantation such that with every 1 μm increase in blastocyst size, there was a relative increase in the odds of implantation by 2.1 per cent.
Applying CHLOE to assess these parameters retrospectively, was possible due to CHLOE’s advanced, consistent and automated assessment.
These capabilities enable researchers to study various events, biomarkers, timing and ratios objectively that were previously not possible, providing new insights for treatment decisions and opening up tremendous opportunity for more research to advance the field.
“CHLOE’s AI algorithms enabled us to measure various embryo components automatically with higher accuracy and speed than us, the embryologists,” explained Professor Har Vardi.
“As a researcher and a clinical embryologist, AI provides a powerful new tool and opens endless possibilities to further explore basic science and clinical parameters.

Professor Iris Har Vardi, director of Fertility and IVF Lab at Soroka University Medical Center and senior lecturer at Ben Gurion University
“This research highlights the potential for enhanced blastocyst selection in the IVF process using AI technology, which offers great promise for improving the effectiveness and personalisation of reproductive healthcare.”
Researchers can utilise CHLOE to further their understanding of embryo and oocyte development that may enhance current workflows, protocols and practice of reproductive health care.
Eran Eshed, co-founder and CEO of Fairtility, said: “Our mission at Fairtility is to advance and improve reproductive care through CHLOE, our AI powered software platform.
“We promote this in clinical settings through our product offerings and in academic settings to advance the science and understanding of reproductive health.
“We can leverage AI technologies to elevate care in clinics, and ensure researchers continue to advance our understanding to improve patient care in the long term.”
CHLOE is currently being used in tens of clinics around the world. Clinicians utilise CHLOE EQ for automated embryo quality assessment in IVF, CHLOE OQ to support oocyte assessment for fertility preservation, egg donation and in IVF decision making, and CHLOE KPI for clinical and operational performance monitoring.

Menopause
Hormone therapy users report healthier lifestyles

Menopausal women using hormone therapy reported healthier diet, exercise and sleep habits than non-users in a study of more than 10,000 women.
The menopause transition is associated with a higher risk of chronic health conditions and symptoms including hot flushes and problems affecting the urinary and genital systems.
Hormone therapy is often used to manage these symptoms, but it remains unclear whether it affects health outcomes directly or indirectly through changes in health behaviours.
Previous research has produced mixed results, with some studies suggesting that postmenopausal women pay greater attention to maintaining a healthy lifestyle.
The cross-sectional analysis examined whether menopause status and hormone therapy use were linked to diet, physical activity and sleep duration.
A cross-sectional study assesses participants at one point in time. It can identify associations but cannot establish whether one factor directly caused another.
Diet, exercise and sleep are described as modifiable health behaviours because people may be able to change them to improve their health.
The researchers found that postmenopausal women who had never used hormone therapy reported eating less fruit and vegetables.
Women who had never used the treatment were also 19 per cent less likely to meet guidelines for muscle-strengthening activity.
Sleep duration was shorter among postmenopausal women who had never used hormone therapy.
Compared with premenopausal and perimenopausal women, the likelihood of meeting sleep guidelines was 14 per cent lower among never-users, 26 per cent lower among current users and 24 per cent lower among past users.
Perimenopause is the transitional period before menopause, when hormone levels and menstrual periods can change.
Researchers said these findings may be linked to higher levels of follicle-stimulating hormone among postmenopausal women who do not use hormone therapy.
They may also relate to lower levels of oestradiol, a form of oestrogen, which have previously been associated with poorer sleep.
Hot flushes and urogenital symptoms can also disrupt sleep, although hormone therapy may ease these symptoms.
Dr Stephanie Faubion, medical director for The Menopause Society, said: “This large observational study underscores that women who use hormone therapy tend to adopt overall healthier lifestyles.
“Although this association may partly reflect better symptom control enabling healthier behaviours, healthy-user bias is likely a significant contributor.
“Women who choose to use hormone therapy are often more proactive in their healthcare and may systematically differ from nonusers in socioeconomic resources, access to care, and health literacy.
“This largely explains why early observational studies of hormone therapy suggested cardiovascular benefits that were not confirmed in subsequent randomised, controlled trials.”
Wellness
Strength training may lower heart disease risk in women, study suggests

Women who do strength training may have a lower risk of major cardiovascular disease, particularly alongside aerobic activity, a study suggests.
Cardiovascular disease is the leading cause of death worldwide. Aerobic activities such as brisk walking, jogging, cycling and swimming are already established ways to help reduce the risk.
Strength or resistance training, also known as RT, is less established as a prevention strategy. It makes muscles work against a force and can involve body weight, free weights, resistance bands or machines.
Current US guidelines recommend at least two days of strength training and 150 minutes of moderate-to-vigorous aerobic activity each week.
They also recommend limiting sedentary behaviour, including prolonged television viewing, which is considered an independent risk factor for cardiovascular disease.
Dr Tianyue Zhang, lead study author and scientist in the department of nutrition at the Harvard T.H. Chan School of Public Health, said: “Despite its established health benefits, RT is often overlooked as a prevention strategy for CVD, and its impact on CVD risk, especially in middle-aged and older women, remains understudied.
“A key question is, how much does it add beyond aerobic activity alone?”
Researchers analysed data from 117,025 women participating in the Nurses’ Health Study and Nurses’ Health Study II.
The two groups had average starting ages of 66.8 and 48.1 years respectively.
The women reported their resistance training every four years, with exercises involving the arms and legs recorded separately.
Time spent watching television was used as the main measure of sedentary behaviour.
The researchers examined exercise and television-viewing habits alongside the incidence of major cardiovascular disease.
Major cardiovascular events included fatal or non-fatal heart attacks, strokes, coronary artery bypass surgery and percutaneous coronary intervention.
Coronary artery bypass surgery redirects blood around narrowed or blocked heart arteries. Percutaneous coronary intervention uses a small balloon, often followed by a stent, to open a narrowed artery.
Higher levels of strength training were associated with a lower risk of major cardiovascular disease, particularly heart attacks.
No statistically significant link with stroke was found when resistance exercise was considered separately.
Women completing at least two hours of strength training a week had a 20 per cent lower risk of major cardiovascular disease and a 44 per cent lower risk of heart attack than those doing none.
Each additional hour a week was associated with a five per cent lower risk of major cardiovascular disease and a 14 per cent lower risk of heart attack.
The associations weakened somewhat after researchers accounted for body mass index and conditions including diabetes, high blood pressure and high cholesterol, but remained clear.
Body mass index, or BMI, compares weight with height and is commonly used to assess whether someone is within a healthy weight range.
Strength training was also linked to additional benefits among women who did aerobic activity.
Women completing at least two hours of strength training and 150 minutes of aerobic activity each week had a 45 per cent lower risk of heart attack than those reporting no physical activity.
Women who met recommendations for strength training, aerobic activity and reduced television viewing had the lowest risks of major cardiovascular disease, heart attack and stroke compared with those who met some or none of the recommendations.
Zhang said: “These findings suggest that, within an already active population, RT is associated with additional reductions in CVD risk above and beyond overall aerobic activity.
“Alongside aerobic activity and reductions in sedentary behaviour, RT may be an important component of public health strategies for cardiovascular prevention in women.”
The study relied on participants reporting their own resistance training, meaning the data may not always have been precise.
Researchers also noted the possible influence of unmeasured factors and the limited diversity of participants.
They were unable to fully separate the effects of the type of resistance training performed from the overall amount completed.
Dr Harlan M. Krumholz, professor at Yale School of Medicine, said: “We have long encouraged resistance training, and this study provides strong evidence to reinforce that message.
“It should be included in a well-rounded health routine to support function and longevity.”
Pregnancy
Women with pre-eclampsia at increased risk of chronic kidney disease, study finds

Women who develop pre-eclampsia face a higher risk of chronic kidney disease and high blood pressure later in life, new research suggests.
The amount of protein found in the urine during pregnancy may help identify those at greatest risk of developing long-term health problems.
Pre-eclampsia usually involves high blood pressure and increased protein in the urine. Some women also experience severe headaches and changes to their vision.
The condition cannot be treated during pregnancy and, in some cases, labour must be induced early to protect both the woman and baby.
The study found that the condition may be linked to longer-term health problems.
Anne Høy Seemann Vestergaard, a medical doctor and PhD at the department of clinical medicine at Aarhus University, said: “What we can see is a clear association between pre-eclampsia and the development of high blood pressure, chronic kidney disease and cardiovascular disease later in life.”
The researchers found that the amount of protein passed in the urine during pregnancy was linked to the risk of developing chronic conditions after giving birth.
Protein in the urine can indicate that the kidneys are not filtering blood normally.
Vestergaard said: “The most surprising finding was how clearly the amount of protein in the urine during pre-eclampsia was linked to the risk of later high blood pressure and chronic kidney disease. Women with moderate to severe protein excretion had a higher risk of both conditions compared with women with low or no protein excretion.”
Among women with pre-eclampsia and moderate to severe levels of protein in the urine, around one in 20 developed chronic kidney disease within 10 years and around one in six developed high blood pressure.
Most women in the study did not develop long-term complications, but the researchers said the increased risk should still be taken seriously because the potential effects can be severe.
Vestergaard said: “At first glance, this may sound like a low number, but it represents a markedly increased risk when the groups are compared. In the group with pre-eclampsia and high levels of protein in the urine, around 1 in 20 women developed chronic kidney disease within ten years, including early stages of the disease, compared with around 1 in 100 in the group with lower or no protein excretion.”
She added: “That is a considerable number in light of the fact that chronic kidney disease is a potentially serious condition that can progress to kidney failure if isn’t diagnosed early.”
The findings suggest women who experience pre-eclampsia may benefit from more systematic monitoring after pregnancy.
Vestergaard said: “Our study suggests that these women may benefit from monitoring of blood pressure and kidney function after pregnancy.”
Menopause4 weeks agoPerimenopause misinformation ‘putting women at risk’
Events4 weeks agoWomen’s Health Innovation Summit opens submissions for 2026 Innovation Showcase
News3 weeks agoWomen still being failed when they reach menopause, experts say
Insight2 weeks agoBritish women among angriest in Europe, health survey reveals
Menopause4 weeks agoSweden eyes domestic production of oestrogen patches amid menopause treatment shortage
News1 week agoFemtech World Awards 2026: Winners revealed
News3 weeks agoThree menopause innovators shortlisted for Femtech World Award
Menopause2 weeks agoApple Health adds menopause and perimenopause tracking














Pingback: Study shows CHLOE AI’s role in advancing reproductive health research - Fairtility